As per the file enclosed

Venus Remedies reported strong FY2026 results with standalone revenue of Rs 768.73 Cr (up 19.3% from Rs 644.47 Cr in FY2025) and consolidated revenue of Rs 769.60 Cr. Net profit after tax grew significantly to Rs 99.31 Cr standalone and Rs 102.78 Cr consolidated, compared to Rs 52.55 Cr and Rs 45.31 Cr respectively in the previous year. EPS improved to Rs 74.29 (standalone) and Rs 76.89 (consolidated) from Rs 39.32 and Rs 33.89. The Board recommended a final dividend of Rs 10 per share (100%) payable after shareholder approval at the 37th AGM on 20th August 2026 (record date: 7th August 2026). Key board changes include reappointment of Mr. Saransh Chaudhary as Managing Director and appointment of Dr. Savita Gupta as Additional Director (related party). The company adopted new MOA and AOA aligned with Companies Act 2013. Auditors issued an unmodified (clean) opinion on both standalone and consolidated financial statements.